| XLS |
|
Information by division |
||||||||||||||||||||
|
|
|
|
|
|
|
|
||||||||||||||
|
|
|
|
|
|
|
|
||||||||||||||
|
|
Merck Serono |
Consumer Health |
Performance Materials |
|||||||||||||||||
|
€ million |
2013 |
2012 |
2013 |
2012 |
2013 |
2012 |
||||||||||||||
|
||||||||||||||||||||
|
Sales |
5,953.6 |
5,995.8 |
476.9 |
472.6 |
1,642.1 |
1,674.2 |
||||||||||||||
|
Royalty, license and commission income |
372.2 |
409.4 |
2.7 |
2.6 |
2.3 |
1.4 |
||||||||||||||
|
Total revenues |
6,325.8 |
6,405.2 |
479.6 |
475.2 |
1,644.4 |
1,675.6 |
||||||||||||||
|
Gross margin |
5,219.7 |
5,212.1 |
318.3 |
316.7 |
1,028.5 |
959.1 |
||||||||||||||
|
Marketing and selling expenses |
–1,288.7 |
–1,370.8 |
–213.0 |
–218.5 |
–140.5 |
–142.8 |
||||||||||||||
|
Royalty, license and commission expenses |
–547.7 |
–561.6 |
–2.0 |
–1.0 |
–1.3 |
–1.5 |
||||||||||||||
|
Administration expenses1 |
–211.3 |
–216.8 |
–18.1 |
–19.9 |
–27.8 |
–31.2 |
||||||||||||||
|
Other operating expenses and income1 |
–499.4 |
–669.0 |
–3.5 |
–46.2 |
–47.9 |
–32.0 |
||||||||||||||
|
Research and development |
–1,182.8 |
–1,187.3 |
–17.1 |
–19.4 |
–143.0 |
–137.4 |
||||||||||||||
|
Operating result (EBIT)1 |
893.0 |
547.7 |
62.2 |
7.6 |
653.3 |
609.7 |
||||||||||||||
|
Depreciation and amortization |
797.4 |
881.1 |
8.6 |
11.5 |
107.7 |
114.1 |
||||||||||||||
|
Impairment losses |
196.4 |
51.2 |
0.3 |
10.7 |
9.3 |
12.1 |
||||||||||||||
|
Reversals of impairment losses |
–0.3 |
– |
– |
– |
–4.5 |
–1.3 |
||||||||||||||
|
EBITDA1 |
1,886.5 |
1,480.0 |
71.1 |
29.8 |
765.8 |
734.6 |
||||||||||||||
|
One-time items |
68.5 |
344.7 |
1.4 |
37.0 |
13.9 |
7.3 |
||||||||||||||
|
EBITDA pre one-time items (segment result)1 |
1,955.0 |
1,824.7 |
72.5 |
66.8 |
779.7 |
741.9 |
||||||||||||||
|
EBITDA margin pre one-time items (in % of sales)1 |
32.8 |
30.4 |
15.2 |
14.1 |
47.5 |
44.3 |
||||||||||||||
|
Net operating assets |
6,968.0 |
8,020.6 |
258.2 |
283.8 |
1,044.7 |
1,187.7 |
||||||||||||||
|
Segment liabilities |
–1,358.0 |
–1,349.8 |
–74.5 |
–76.5 |
–155.9 |
–147.1 |
||||||||||||||
|
Investments in property, plant and equipment2 |
151.3 |
146.9 |
3.7 |
4.0 |
66.5 |
55.7 |
||||||||||||||
|
Investments in intangible assets2 |
80.6 |
88.7 |
0.4 |
0.4 |
6.7 |
28.6 |
||||||||||||||
|
Net cash flows from operating activities1 |
1,818.9 |
2,255.6 |
67.1 |
75.6 |
828.4 |
886.6 |
||||||||||||||
|
Business free cash flow1 |
1,875.7 |
1,880.2 |
83.9 |
88.8 |
787.8 |
798.1 |
||||||||||||||
|
|
|
|
|
|
|
|
||||||||||||||
|
|
|
|
|
|
|
|
||||||||||||||
|
|
Merck Millipore |
Corporate and Other |
Group |
|||||||||||||||||
|
€ million |
2013 |
2012 |
2013 |
2012 |
2013 |
2012 |
||||||||||||||
|
Sales |
2,627.5 |
2,598.2 |
– |
– |
10,700.1 |
10,740.8 |
||||||||||||||
|
Royalty, license and commission income |
17.8 |
18.7 |
– |
– |
395.0 |
432.1 |
||||||||||||||
|
Total revenues |
2,645.3 |
2,616.9 |
– |
– |
11,095.1 |
11,172.9 |
||||||||||||||
|
Gross margin |
1,541.0 |
1,531.1 |
–4.9 |
–3.8 |
8,102.6 |
8,015.2 |
||||||||||||||
|
Marketing and selling expenses |
–683.3 |
–675.7 |
–1.0 |
–3.0 |
–2,326.5 |
–2,410.8 |
||||||||||||||
|
Royalty, license and commission expenses |
–16.1 |
–15.7 |
0.1 |
– |
–567.0 |
–579.8 |
||||||||||||||
|
Administration expenses1 |
–99.2 |
–101.3 |
–206.0 |
–183.0 |
–562.4 |
–552.2 |
||||||||||||||
|
Other operating expenses and income1 |
–120.7 |
–116.5 |
–46.6 |
–262.2 |
–718.1 |
–1,125.9 |
||||||||||||||
|
Research and development |
–159.8 |
–166.1 |
–1.6 |
–1.1 |
–1,504.3 |
–1,511.3 |
||||||||||||||
|
Operating result (EBIT)1 |
262.0 |
251.7 |
–259.7 |
–453.1 |
1,610.8 |
963.6 |
||||||||||||||
|
Depreciation and amortization |
309.2 |
305.0 |
15.0 |
7.6 |
1,237.9 |
1,319.3 |
||||||||||||||
|
Impairment losses |
18.8 |
4.2 |
0.8 |
0.5 |
225.6 |
78.7 |
||||||||||||||
|
Reversals of impairment losses |
–0.2 |
– |
–0.1 |
–0.1 |
–5.1 |
–1.4 |
||||||||||||||
|
EBITDA1 |
589.8 |
560.9 |
–244.0 |
–445.1 |
3,069.2 |
2,360.2 |
||||||||||||||
|
One-time items |
53.0 |
53.5 |
47.3 |
162.2 |
184.1 |
604.7 |
||||||||||||||
|
EBITDA pre one-time items (segment result)1 |
642.8 |
614.4 |
–196.7 |
–282.9 |
3,253.3 |
2,964.9 |
||||||||||||||
|
EBITDA margin pre one-time items (in % of sales)1 |
24.5 |
23.6 |
– |
– |
30.4 |
27.6 |
||||||||||||||
|
Net operating assets |
5,987.1 |
6,328.9 |
36.0 |
25.1 |
14,294.0 |
15,846.1 |
||||||||||||||
|
Segment liabilities |
–391.9 |
–383.1 |
–64.8 |
–33.7 |
–2,045.1 |
–1,990.2 |
||||||||||||||
|
Investments in property, plant and equipment2 |
112.6 |
113.2 |
72.9 |
9.3 |
407.0 |
329.1 |
||||||||||||||
|
Investments in intangible assets2 |
10.3 |
10.0 |
11.6 |
16.5 |
109.6 |
144.2 |
||||||||||||||
|
Net cash flows from operating activities1 |
557.5 |
658.2 |
–1,046.4 |
–1,403.8 |
2,225.5 |
2,472.2 |
||||||||||||||
|
Business free cash flow1 |
493.8 |
511.3 |
–281.2 |
–309.1 |
2,960.0 |
2,969.3 |
||||||||||||||
| XLS |
|
Information by country and region |
||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Europe |
thereof Germany |
thereof France |
|||
|
€ million |
2013 |
2012 |
2013 |
2012 |
2013 |
2012 |
|
Sales by customer location |
3,984.6 |
3,942.7 |
825.4 |
801.5 |
677.0 |
696.0 |
|
Sales by company location |
4,457.5 |
4,379.9 |
1,570.8 |
1,452.9 |
790.8 |
814.9 |
|
Total revenues |
4,686.6 |
4,677.0 |
1,596.8 |
1,472.7 |
812.5 |
822.0 |
|
Intangible assets |
7,572.4 |
8,293.4 |
398.0 |
344.9 |
278.0 |
302.1 |
|
Property, plant and equipment |
2,075.2 |
2,344.3 |
997.5 |
996.4 |
183.6 |
173.9 |
|
Research and development |
–1,357.4 |
–1,344.1 |
–849.0 |
–791.8 |
–56.4 |
–56.0 |
|
Number of employees |
20,013 |
20,777 |
10,868 |
10,788 |
2,946 |
2,950 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
thereof Switzerland |
North America |
thereof USA |
|||
|
€ million |
2013 |
2012 |
2013 |
2012 |
2013 |
2012 |
|
Sales by customer location |
159.0 |
141.6 |
2,078.0 |
2,128.3 |
1,916.8 |
1,965.0 |
|
Sales by company location |
188.6 |
174.2 |
2,072.7 |
2,121.4 |
1,933.1 |
1,979.0 |
|
Total revenues |
364.5 |
438.4 |
2,077.1 |
2,122.1 |
1,937.5 |
1,979.7 |
|
Intangible assets |
4,692.3 |
5,343.0 |
2,214.8 |
2,462.1 |
2,214.5 |
2,461.6 |
|
Property, plant and equipment |
508.0 |
795.2 |
341.6 |
359.6 |
340.4 |
358.3 |
|
Research and development |
–411.4 |
–462.1 |
–92.5 |
–114.5 |
–94.7 |
–113.3 |
|
Number of employees |
1,232 |
1,926 |
4,911 |
4,848 |
4,754 |
4,688 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Emerging Markets |
Rest of World |
Group |
|||
|
€ million |
2013 |
2012 |
2013 |
2012 |
2013 |
2012 |
|
Sales by customer location |
3,795.6 |
3,712.2 |
841.9 |
957.6 |
10,700.1 |
10,740.8 |
|
Sales by company location |
3,467.1 |
3,408.4 |
702.8 |
831.1 |
10,700.1 |
10,740.8 |
|
Total revenues |
3,622.3 |
3,542.7 |
709.1 |
831.1 |
11,095.1 |
11,172.9 |
|
Intangible assets |
46.5 |
141.3 |
33.5 |
47.7 |
9,867.2 |
10,944.5 |
|
Property, plant and equipment |
169.3 |
163.7 |
61.1 |
86.0 |
2,647.2 |
2,953.6 |
|
Research and development |
–36.6 |
–28.6 |
–17.8 |
–24.1 |
–1,504.3 |
–1,511.3 |
|
Number of employees |
11,688 |
11,642 |
1,542 |
1,580 |
38,154 |
38,847 |

search hit 15